XEN-D0501
Xention (Originator)
XEN-D0501, a novel TRPV1 antagonist, is being developed to treat overactive bladder.
in phase 2 Chronic obstructive pulmonary disease (COPD)
Ario Kicks Off Efficacy Trial of Chronic Idiopathic Cough Drug
Ario Pharma Ltd, the biopharmaceutical company developing innovative new treatments for respiratory disease, announced that it has commenced a Phase 2a study of its oral TRPV1 antagonist, XEN-D0501, for the treatment and prevention of cough in patients with chronic idiopathic cough (CIC).http://www.dddmag.com/news/2014/07/ario-kicks-efficacy-trial-chronic-idiopathic-cough-drug?et_cid=4039308&et_rid=523035093&type=cta
Filed under: Phase2 drugs Tagged: Ario, overactive bladder, Pharma Ltd, respiratory disease, XEN-D0501
